INFLUENCE OF CpG ODN 2006 OLIGODEOXYNUCLEOTIDE ON CYTOKINE PRODUCTION BY BLOOD CELLS OF HUMANS VACCINATED AGAINST PLAGUE
https://doi.org/10.15789/1563-0625-2014-6-531-538
Abstract
This study presents data upon the effects of CpG oligonucleotide substance (CpG ODN 2006). The commercial preparation was applied in vitro as a single agent, or in combination with various cytokine production inducers. Spontaneous and induced cytokine levels were tested in cultures of human blood cells taken from the persons before and after anti-plague vaccination. It has been shown that the vaccination had no effect upon spontaneous production of cytokines participating in innate (IL-8, TNFα) and adaptive (IFNγ, IL-4) immunity. CpG ODN 2006 proved to exert effects upon functional activity of human blood Th1 and Th2 pro-inflammatory cytokines after the first vaccination with live anti-plague vaccine, being reflected as higher Th1/ proinflammatory (IL-17 and IFNг) and Th2/ antiinflammatory (IL-4) cytokine production. Postvaccination changes of IgM, IgG, IgA, and IgE contents were non-significant. Following repeated vaccination, the CpG ODN 2006 induced an increase of IL-4 and IL-17 production in blood cells, as well as decrease in IFNг levels. Thus, the ability of CpG ODN 2006 to activate the cells participating in innate and adaptive immunity opens some prospects for usage of this oligodeoxynucleotide in the development of more efficient anti-plague vaccines.
About the Authors
S. N. Klyueva
Russian Research Anti-Plague Institute “Microbe”, Saratov, Russian Federation
Russian Federation
Russian Federation
T. P. Shmelkova
Russian Research Anti-Plague Institute “Microbe”, Saratov, Russian Federation
Russian Federation
Russian Federation
T. N. Schukovskaya
Russian Research Anti-Plague Institute “Microbe”, Saratov, Russian Federation
Russian Federation
Russian Federation
410005, Russian Federation, Saratov, Universitetskaya str., 46.
Phone: 8 (8452) 26-21-31. Fax: 8 (8452) 51-52-12
References
1. Богачева Н.В., Дармов И.В., Кучеренко А.С., Крючков А.В., Вахнов Е.Ю. Оценка иммунореактивности лиц, вакцинированных чумной, сибиреязвенной, бруцеллезной, туляремийной живыми сухими вакцинами и противоботулиническим трианатоксином, в зависимости от уровня иммунологической нагрузки // Эпидемиология и вакцинопрофилактика, 2013. Т. 73, № 6. С. 79-84. [Bogacheva N.V., Darmov I.V., Kucherenko A.S., Kryuchkov A.V., Vahnov E.Yu. Evaluation of immunoreactivity of persons vaccinated plague, anthrax, brucellosis, tularemia vaccine dry alive and protivobotulinicheskim trianatoksinom, depending on the level of immunological load. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2013, Vol. 73, no. 6, pp. 79-84. (In Russ.)]
2. Бугоркова С.А., Девдариани З.Л., Щуковская Т.Н., Кутырев В.В. Исторические и современные представления о проблеме специфической профилактики чумы // Проблемы особо опасных инфекций, 2013. № 3. С. 63-69.
3. Вакцины и вакцинация: национальное руководство / под ред. В. В. Зверева, Б. Ф. Семенова, Р.М. Хаитова. М.: ГЭОТАР-Медиа, 2011. 872 с. [Vaccines and vaccination: national leadership / ed. V.V. Zverev, B.F. Semenov, R.M. Haitov]. Moscow, GEOTAR Media, 2011, 872 p.
4. Долгов В.В., Ракова Н.Г., Колупаев В.Е., Рытикова Н.С. Иммуноферментный анализ в клинико-диагностических лабораториях. М.-Тверь: Триада, 2007. 320 с. [Dolgov V.V., Rakov N.G., Kolupaev V.E., Rytikova N.S. Enzyme-linked immunosorbent assay in clinical diagnostic laboratories]. Moscow-Tver: Triad, 2007, 320 p.
5. Кетлинский С.А. Цитокины / С.А. Кетлинский, А.С. Симбирцев. СПб.: Фолиант, 2008. 552 c.
6. [Ketlinsky S.A. Cytokines / S.A. Ketlinsky, A.S. Simbirtsev]. St. Petersburg: Folio, 2008, 552 p.
7. Коробкова Е.И. Кожная аллергическая реакция как показатель иммунитета при чуме // Журнал микробиологии, эпидемиологии и иммунобиологии, 1955. № 4. С. 40-47. [Korobkova E.I. Allergic skin reactions as a measure of immunity in plague. Journal of Epidemiology. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology, 1955, Vol. 4, pp. 40-47. (In Russ.)].
8. Медицинские лабораторные технологии. Т. 2. Справочник / под ред. А.И. Карпищева. СПб: Интермедика, 2002. 600 с. [Medical laboratory technologies. V.2. / Ed. AI Karpischeva]. St. Petersburg: Intermedika, 2002, 600 p.
9. Щуковская Т.Н., Смолькова Е.А., Шмелькова Т.П., Клюева С.Н., Бугоркова С.А. Индуцированная продукция IFN-γ и IL-4 как показатель функциональной активности Th1- и Th2-клеток у вакцинированных против чумы людей // Эпидемиология и вакцинопрофилактика, 2011. Т. 61, № 6. С. 78-83. [Schukovskaya T.N., Smolkova E.A., Shmelkova T.P., Klyuyeva S.N., Bugorkova S.A. Induced production of IFN-γ and IL-4 as a measure of functional activity of Th1-and Th2-cells from individuals vaccinated against plague. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2011, Vol. 61, no. 6, pp. 78-83. (In Russ.)]
10. Al-Mariri A., Tibor A., Mertens P., De Bolle X., Michel P., Godefroid J., Walravens K., Letesson J.J. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun, 2001, Vol. 69, no. 8, pp. 4816-4822.
11. Amemiya K., Meyers J.L., Rogers T.E., Fast R.L., Bassett A.D., Worshama P.L., Powell B.S., Norris S.L., Krieg A.M., Adamovicz J.J. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine, 2009, Vol. 27, pp. 2220-2229.
12. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines, 2011, Vol. 10, no. 4, pp. 499-511.
13. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., Cameron D.W., Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol., 2004, Vol. 24, no. 6, pp. 693-701.
14. Hickey A.J., Lin J-S., Kummer L.W., Szaba F.M., Duso D. K., Tighe M., Parent M.A., Smiley S.T. Intranasal Prophylaxis with CpG Oligodeoxynucleotide Can Protect against Yersinia pestis Infection. Infect. Immun., 2013, Vol. 81, no. 6, pp. 2123-2132.
15. Huang C.F., Wang C.C., Wu T.C., Wu K.G., Lee C.C., Peng H.J. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice. J. Pediatr. Gastroenterol. Nutr., 2008, Vol. 46, no. 3, pp. 262-271.
16. Judy B.M., Taylor K., Deeraksa A., Johnston R.K., Endsley J.J., Vijayakumar S., Aronson J.F., Estes D.M., Torres A.G. Prophylactic Application of CpG Oligonucleotides Augments the Early Host Response and Confers Protection in Acute Melioidosis. PLoS ONE, 2012, Vol. 7, no. 3, e34176.
17. Kajiwara A., Doi H., Eguchi J., Ishii S., Hiraide-Sasagawa A., Sakaki M., Omori R., Hiroishi K., Imawari M. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses. Oncol. Rep., 2012, Vol. 27, no. 6, pp.1765-1771.
18. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv. Drug. Deliv. Rev., 2009, Vol. 61, no. 3, pp. 248-255.
19. Lin J.S., Kummer L.W., Szaba F.M., Smiley S.T. IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J. Immunol., 2011, Vol. 186, pp. 1675-1684.
20. Parent M.A., Wilhelm L.B., Kummer L.W., Szaba F.M., Mullarky I.K., Smiley S.T. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect. Immun., 2006, Vol. 74, pp. 3381-3386.
21. Rosenzweig J.A., Jejelowo O., Sha J., Erova T.E. Progress on plague vaccine development. Appl. Microbiol. Biotechnol., 2011, Vol. 91, pp. 265-286.
22. Vollmer J., Jurk M., Samulowitz U., Lipford G., Forsbach A., Wullner M., Tluk S., Hartmann H., Kritzler A., Muller C., Schetter C., Krieg A.M. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J. Endotoxin. Res., 2004, Vol. 10, pp. 431-438.
Review
For citations:
Klyueva S.N., Shmelkova T.P., Schukovskaya T.N. INFLUENCE OF CpG ODN 2006 OLIGODEOXYNUCLEOTIDE ON CYTOKINE PRODUCTION BY BLOOD CELLS OF HUMANS VACCINATED AGAINST PLAGUE. Medical Immunology (Russia). 2014;16(6):531-538. (In Russ.) https://doi.org/10.15789/1563-0625-2014-6-531-538
Views:
956
Email this article 